Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Palisade Bio Inc (PALI)

Palisade Bio Inc (PALI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,307
  • Shares Outstanding, K 852
  • Annual Sales, $ 250 K
  • Annual Income, $ -12,300 K
  • 60-Month Beta 1.33
  • Price/Sales 21.64
  • Price/Cash Flow N/A
  • Price/Book 0.32
Trade PALI with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -8.10
  • Growth Rate Est. (year over year) +12,433.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.82 +59.69%
on 04/12/24
9.65 -36.79%
on 04/16/24
+0.51 (+9.08%)
since 03/26/24
3-Month
3.82 +59.69%
on 04/12/24
22.35 -72.71%
on 01/29/24
-1.70 (-21.79%)
since 01/26/24
52-Week
3.82 +59.69%
on 04/12/24
36.60 -83.33%
on 07/26/23
-18.05 (-74.74%)
since 04/26/23

Most Recent Stories

More News
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023

- Live video webcast interactive Q&A with participating companies -

EVFM : 0.0157 (+10.56%)
GRI : 0.4300 (-0.05%)
MBRX : 4.79 (+11.18%)
XBIO : 4.09 (+8.32%)
AREC : 1.5600 (+8.33%)
CNSP : 0.2092 (+2.55%)
NVNO : 5.12 (-2.10%)
PALI : 6.09 (-2.25%)
Palisade Bio, Inc. (PALI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Palisade Bio, Inc. (PALI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate...

PALI : 6.09 (-2.25%)
Palisade (PALI) Enrolls First Patient in LB1148 Study in China

Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.

CRSP : 53.16 (-1.06%)
KALA : 6.31 (+2.10%)
KOD : 3.26 (+2.52%)
PALI : 6.09 (-2.25%)
What Makes Palisade Bio, Inc. (PALI) a New Buy Stock

Palisade Bio, Inc. (PALI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PALI : 6.09 (-2.25%)
Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation

Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.

AVEO : 15.00 (unch)
ETON : 3.67 (+17.63%)
IMCR : 58.39 (+0.67%)
PALI : 6.09 (-2.25%)
Palisade Bio (NASDAQ: PALI) Awarded Fast Track Designation from U.S. FDA for LB1148

Palisade Bio, Inc. (NASDAQ: PALI) is engaged as a biopharmaceutical company, which is focused on the research and development of

PALI : 6.09 (-2.25%)
Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health

New website aligns with company’s mission to become a global leader in addressing diseases linked to intestinal barrier disruption and establishing new...

PALI : 6.09 (-2.25%)
Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for...

PALI : 6.09 (-2.25%)
Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function

Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies, LB1148 has demonstrated statistically significant...

PALI : 6.09 (-2.25%)
Palisade Bio to Present at the 2022 BIO International Convention

In-person presentation on Monday, June 13th at 1:45 PM PT...

PALI : 6.09 (-2.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 7.19
2nd Resistance Point 6.80
1st Resistance Point 6.51
Last Price 6.09
1st Support Level 5.83
2nd Support Level 5.44
3rd Support Level 5.15

See More

52-Week High 36.60
Fibonacci 61.8% 24.08
Fibonacci 50% 20.21
Fibonacci 38.2% 16.34
Last Price 6.09
52-Week Low 3.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar